Teprotumumab-Trbw
Brand name: Tepezza
Rank #410 of 500 drugs by total cost
$21.4M
Total Cost
389
Total Claims
$21.4M
Total Cost
24
Prescribers
$55K
Cost per Claim
0
Beneficiaries
389
30-Day Fills
$892K
Avg Cost/Provider
16
Avg Claims/Provider
About Teprotumumab-Trbw
Teprotumumab-Trbw (sold as Tepezza) was prescribed 389 times by 24 Medicare Part D providers in 2023, costing the program $21.4M. At $55K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 407 | Ondansetron (Ondansetron Odt) | $21.5M | 1,261,950 |
| 408 | Asciminib Hydrochloride (Scemblix) | $21.4M | 830 |
| 409 | Cephalexin (Cephalexin) | $21.4M | 2,407,718 |
| 410 | Teprotumumab-Trbw (Tepezza) | $21.4M | 389 |
| 411 | Nystatin (Nystatin) | $21.4M | 908,177 |
| 412 | Desvenlafaxine Succinate (Desvenlafaxine Succinate Er) | $21.3M | 257,580 |
| 413 | Sotorasib (Lumakras) | $21.3M | 1,188 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology